eukaryotic translation initiation factor 4E binding protein 3Genealiases: 4E-BP3 · 4EBP3
Q-omics provides the consensus-scored EIF4EBP3 profile across patient tissues and cancer cell-line models. EIF4EBP3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, EIF4EBP3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, EIF4EBP3 RNA expression shows 12,940 significant gene co-expression associations, with the highest sampling consensus in MESO. Together, these results highlight ACC, KIRC, and MESO as cancer lineages where EIF4EBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4EBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4EBP3 survival associations across molecular data types. EIF4EBP3 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4EBP3 RNA expression–survival associations across cancer types. High EIF4EBP3 expression shows unfavorable associations in UVM, but favorable associations in ACC, HNSC, MESO, READ and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for EIF4EBP3 RNA expression.
This table summarizes EIF4EBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EIF4EBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4EBP3 shows lower tumor expression in HNSC, BLCA, LUAD and UCEC and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher EIF4EBP3 RNA expression in tumor versus normal tissue (log2 FC = +1.616, t-test p < 0.001).
This table shows molecular features associated with EIF4EBP3 in patient tissues and cancer cell lines. In patient samples, EIF4EBP3 shows the broadest associations at the RNA and protein expression levels, with MESO recurring as the lineage with the largest associated feature set. In cancer cell lines, EIF4EBP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
